Search research articles
Contact Us
Filters
Showing results (21-30 of 44) with videos related to
Page
of 5
Sort By:
Bioconjugate Chemistry
|
January 22, 2016
Synthesis and Evaluation of Astatinated N-[2-(Maleimido)ethyl]-3-(trimethylstannyl)benzamide Immunoconjugates
Emma Aneheim, Anna Gustafsson, Per Albertsson, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
December 7, 2005
211At radioimmunotherapy of subcutaneous human ovarian cancer xenografts: evaluation of relative biologic effectiveness of an alpha-emitter in vivo
Tom Bäck, Håkan Andersson, Chaitanya R Divgi, et al.
Translational Oncology
|
September 28, 2020
Evaluation of therapeutic efficacy of <sup>211</sup>At-labeled farletuzumab in an intraperitoneal mouse model of disseminated ovarian cancer
Stig Palm, Tom Bäck, Emma Aneheim, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 25, 2003
Astatine-211-labeled antibodies for treatment of disseminated ovarian cancer: an overview of results in an ovarian tumor model
Håkan Andersson, Jörgen Elgqvist, György Horvath, et al.
Journal of Liposome Research
|
January 15, 2010
Large anti-HER2/neu liposomes for potential targeted intraperitoneal therapy of micrometastatic cancer
Stavroula Sofou, Richard Enmon, Stig Palm, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
November 5, 2005
Therapeutic efficacy and tumor dose estimations in radioimmunotherapy of intraperitoneally growing OVCAR-3 cells in nude mice with (211)At-labeled monoclonal antibody MX35
Jörgen Elgqvist, Håkan Andersson, Tom Bäck, et al.
Frontiers in Medicine
|
January 23, 2023
Astatine-211 based radionuclide therapy: Current clinical trial landscape
Per Albertsson, Tom Bäck, Karin Bergmark, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
July 7, 2022
Estimating the Risk for Secondary Cancer After Targeted α-Therapy with <sup>211</sup>At Intraperitoneal Radioimmunotherapy
Erik Leidermark, Andreas Hallqvist, Lars Jacobsson, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
June 14, 2013
Ex vivo activity quantification in micrometastases at the cellular scale using the α-camera technique
Nicolas Chouin, Sture Lindegren, Sofia H L Frost, et al.
International Journal of Radiation Oncology, Biology, Physics
|
September 18, 2007
Therapeutic efficacy of astatine-211-labeled trastuzumab on radioresistant SKOV-3 tumors in nude mice
Stig Palm, Tom Bäck, Ingela Claesson, et al.
Page
of 5
Search research articles
Search
Showing results (21-30 of 44) with videos related to
Sort By:
Page
of 5
Bioconjugate Chemistry
|
January 22, 2016
Synthesis and Evaluation of Astatinated N-[2-(Maleimido)ethyl]-3-(trimethylstannyl)benzamide Immunoconjugates
Emma Aneheim, Anna Gustafsson, Per Albertsson, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
December 7, 2005
211At radioimmunotherapy of subcutaneous human ovarian cancer xenografts: evaluation of relative biologic effectiveness of an alpha-emitter in vivo
Tom Bäck, Håkan Andersson, Chaitanya R Divgi, et al.
Translational Oncology
|
September 28, 2020
Evaluation of therapeutic efficacy of <sup>211</sup>At-labeled farletuzumab in an intraperitoneal mouse model of disseminated ovarian cancer
Stig Palm, Tom Bäck, Emma Aneheim, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 25, 2003
Astatine-211-labeled antibodies for treatment of disseminated ovarian cancer: an overview of results in an ovarian tumor model
Håkan Andersson, Jörgen Elgqvist, György Horvath, et al.
Journal of Liposome Research
|
January 15, 2010
Large anti-HER2/neu liposomes for potential targeted intraperitoneal therapy of micrometastatic cancer
Stavroula Sofou, Richard Enmon, Stig Palm, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
November 5, 2005
Therapeutic efficacy and tumor dose estimations in radioimmunotherapy of intraperitoneally growing OVCAR-3 cells in nude mice with (211)At-labeled monoclonal antibody MX35
Jörgen Elgqvist, Håkan Andersson, Tom Bäck, et al.
Frontiers in Medicine
|
January 23, 2023
Astatine-211 based radionuclide therapy: Current clinical trial landscape
Per Albertsson, Tom Bäck, Karin Bergmark, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
July 7, 2022
Estimating the Risk for Secondary Cancer After Targeted α-Therapy with <sup>211</sup>At Intraperitoneal Radioimmunotherapy
Erik Leidermark, Andreas Hallqvist, Lars Jacobsson, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
June 14, 2013
Ex vivo activity quantification in micrometastases at the cellular scale using the α-camera technique
Nicolas Chouin, Sture Lindegren, Sofia H L Frost, et al.
International Journal of Radiation Oncology, Biology, Physics
|
September 18, 2007
Therapeutic efficacy of astatine-211-labeled trastuzumab on radioresistant SKOV-3 tumors in nude mice
Stig Palm, Tom Bäck, Ingela Claesson, et al.
Page
of 5